Exactech Announces FDA Clearance of First-to-Market Scapula Reconstruction System for Acromial Stress Fractures
Acromial and scapular fractures are a rare but devastating complication that can occur among every rTSA implant design. The reported rate of acromial and scapular fractures after rTSA averages 2.8 percent but can be as high as 10.9 percent for some patient diagnoses.2 There is currently no accepted treatment solution for patients with this challenging rTSA complication. Recognizing this unmet clinical need, Exactech developed a novel solution to help surgeons treat this unique complication.
Designed by Jonathan Levy, MD, Howard Routman, DO, Peter Cole, MD, George Athwal, MD, Michael McKee, MD, and Joaquin Sanchez-Sotelo, MD, PhD, the Equinoxe Scapula Reconstruction System is the only trauma solution designed to treat acromial and scapular fractures with rTSA in mind.
'We organized a world-class design team to develop this comprehensive scapular plating system, bringing together surgeons with deep and diverse experience with rTSA implant designs from nearly every major manufacturer,' said Chris Roche, Exactech's Sr. Vice President, Extremities. 'This team collaborated to develop what we believe is the definitive treatment solution for acromial and scapular rTSA fracture patterns, an achievement that shows what's possible when surgeons and industry work together to solve challenges. I am proud that Exactech is the first to provide a system with design elements that help support surgeons in managing these complex cases.'
The Equinoxe Scapula Reconstruction System allows orthopedic surgeons to treat scapular fractures using several different techniques, including single and dual plating, regardless of placement of any particular rTSA implant design. This novel system features a versatile portfolio of anatomically contoured plates provided in multiple lengths to enable precise fracture management across the range of patient anatomy with the goal of restoring function.
'Finally, a plating system specifically designed for management of this challenging complication will be available in the United States,' said Howard Routman, DO (Atlantis Orthopedics). 'This dual plating system is impactful because it was designed to not only respect the variable scapular anatomy and variable fracture patterns, but also because it respects the unique biomechanics of the rTSA, which stresses the scapular bone uniquely. The release of this implant will represent a new paradigm for open reduction internal fixation of acromial and scapular spine fractures.'
The Equinoxe Scapula Reconstruction System includes a range of different plate designs incorporating many differentiated features to tailor treatment across the Levy3-4 Type I, II, IIA and IIB fracture classification patterns. Most significantly, each contoured plate includes one or more integral hooks (located anteriorly on the acromion, laterally on the acromion and/or a hook along the medial scapular border) to support the scapula and counteract the pull of the deltoid and the biomechanical loading of the rTSA prosthesis. Previous laboratory research has suggested that the use of a lateral hook plate improved fixation of the lateral acromion.5
'I've spent the better part of my career trying to figure out how and why acromial fractures occur after reverse shoulder replacement,' said Jonathan Levy, MD, Paley Orthopedic and Spine Institute. 'I am proud of the plating system that we have developed – an implant system for acute treatment which will help bring much-needed attention to manage this often-devastating complication.'
Current American Shoulder and Elbow Surgeons President Joaquin Sanchez-Sotelo, Mayo Clinic, added, 'This anatomically contoured dual plating system is designed specifically for treatment of fractures associated with reverse shoulder arthroplasty. It incorporates hooks to brace and support the acromion and is truly a game changer.'
The Equinoxe Scapula Reconstruction System will enter pilot launch with limited availability in the U.S. later this year. For more information, visit www.exac.com.
References
K243275, Equinoxe® Scapula Fracture System
King JJ, et al. How common are acromial and scapular spine fractures after reverse shoulder arthroplasty?: A systematic review. Bone Joint J. 2019 Jun;101-B(6):627-634. doi: 10.1302/0301-620X.101B6.BJJ-2018-1187.R1.
Levy JC, et al. Classification of postoperative acromial fractures following reverse shoulder arthroplasty. J Bone Joint Surg Am. 2013 Aug 7;95(15):e104. doi: 10.2106/JBJS.K.01516.
Boltuch A, et al. Nonoperative treatment of acromial fractures following reverse shoulder arthroplasty: clinical and radiographic outcomes. J Shoulder Elbow Surg. 2022 Jun;31(6S):S44-S56. doi: 10.1016/j.jse.2021.12.024.
Ting FSH, et al. Comparing internal fixation constructs for scapular spine insufficiency fractures following reverse shoulder arthroplasty. J Shoulder Elbow Surg. 2021 Jan;30(1):172-177. doi: 10.1016/j.jse.2020.04.051.
About Exactech
Exactech is a global medical technology leader that empowers orthopaedic surgeons with innovative implants, surgical instruments and the Active Intelligence® (AI) ecosystem of smart technologies to give patients EXACTLY what they need to regain mobility. Visit www.exac.com for more information and connect with us on LinkedIn, Vumedi, YouTube, Instagram and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
MiRus Receives New Technology Add-on Payment (NTAP) for EUROPA™ Posterior Cervical Fusion System
ATLANTA, Aug. 1, 2025 /PRNewswire/ — MiRus has received New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services (CMS) for the EUROPA® Posterior Cervical System, based on it's proprietary rhenium alloys, for treatment of the cervical and upper thoracic spine. The EUROPA® PCF system is built around a 2.9 mm MoRe rod which is much smaller than current commercial systems. The lower diameter rod allows low-profile pedicle screw tulips leading to less invasive surgery and less hardware prominence in smaller patients. Although lower diameter, MoRe rods provide a superior level of rigidity, strength, and fatigue resistance which reduces the risk of spine rod fractures compared to current systems. The EUROPA® PCF System was awarded Breakthrough Device Designation by the FDA. 'I have used the 4.5mm MoRe rod TL system for complex cases and have had good results,' stated Han Jo Kim MD, Professor of Orthopedic Surgery at the Hospital for Special Surgery, New York 'There is tremendous potential in what this proprietary alloy (MoRe) can accomplish in spine surgery, offering implants that are lower profile, more durable and stronger.' 'We are pleased that CMS has recognized the EUROPA® PCF System as the superior option for treating the cervical and upper thoracic spine, enabling hospitals to receive reimbursement through the NTAP program and ensuring Medicare patients have access to this breakthrough technology,' commented Mahesh Krishnan, Chief Commercial Officer. 'Currently the rates of spine implant failures and revision surgeries for patients remain unacceptably high,' commented Jordan Bauman, VP of Regulatory and Quality. 'with EUROPA® PCF, spine surgeons will be able to provide durable and less invasive surgery for their cervicothoracic patients. This is another step forward in our mission to provide less invasive and more durable devices across a broad spectrum of disease states.' About MiRus, is a life sciences company headquartered in Atlanta, Georgia that has developed and is commercializing proprietary novel biomaterials and implants that are transforming medicine by making surgeries less invasive and implants safer and more durable. Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements. The EUROPA® Posterior Cervical System is not FDA approved. * MiRus® , EUROPA®, MoRe® are all trademarks of MiRus, LLC. Contact:Pam CowartVP of Clinical Affairspcowart@
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.
Malaysian Reserve
13 hours ago
- Malaysian Reserve
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ — On 31st July 2025, a unified consensus document for improving lung cancer care in the Asia-Pacific (APAC) region was officially launched in Singapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive consensus for the region, an evidence-based agreement between stakeholders across the healthcare ecosystem that outlines shared priorities, strategies, and recommendations to elevate the standard of lung cancer care across diverse health systems. Held on the eve of World Lung Cancer Day, the initiative involved over 43 contributors, including clinicians, academics, patient advocates, and health organisations across 14 APAC health systems. Launch Highlights and Key Voices The APAC Lung Cancer Policy Consensus was launched with keynote contributions from: Dr Mary Bussell (TriMar Strategies), who delivered an overview of the global lung cancer consensus and its relevance to regional efforts Mr Yannick Romero (Union for International Cancer Control – UICC), who contextualised the APAC consensus within the broader global lung health resolution, emphasising policy alignment and strategic integration Ms Helena Wilcox (The Lung Cancer Policy Network – LCPN), who highlighted how the APAC framework enables regional advancement in care and partnership building Mr Francis Goh (Lung Cancer Education and Advocacy for Patients – LEAP), Singapore) stressed the pivotal role of patient voices in shaping lung cancer policy and health system transformation A/Prof Herbert Loong (Asia Pacific Coalition against Lung Cancer – APCLC) and Asst Prof Yeon Wook Kim (SNU Bundang Hospital), who provided an in-depth presentation on the consensus development process, five key pillars, and concrete calls to action Lung cancer remains the leading cause of cancer-related deaths in the APAC region, and accounts for nearly 60% of global cases. With regional incidence projected to exceed 1.8 million by 2040, the need for a cohesive, regional strategy to combat the disease has never been more urgent. Furthermore, survival rates in the APAC region often lag behind global benchmarks, with five-year survival rates frequently below 20%. This fragmented landscape highlights the critical need for a coordinated approach, one that addresses the unique epidemiological, environmental, and healthcare challenges within the region. The APAC Lung Cancer Policy Consensus is the result of an extensive collaborative process involving two expert working sessions, one patient workshop and a final expert voting session, with input from patients, clinicians and academic leaders across the region. The consensus lays out a unified policy framework anchored in five core principles, all aimed at driving sustainable, equitable improvements in lung cancer prevention, detection, treatment, and stigma reduction across the region. Importantly, the APAC Consensus aligns closely with the Global Lung Cancer Consensus, which was first ratified at the 9th International Lung Cancer Network in 2023. By endorsing this global statement, the APAC region reaffirms its commitment to improving lung cancer outcomes. The Five Global Principles Anchoring the APAC Lung Cancer Policy Consensus: Improve and Expand Prevention Strengthen tobacco control, public education, and environmental risk research to prevent lung cancer across all exposure types Expand screening and diagnostic access through inclusive guidelines and innovative technologies to enable timely lung cancer detection Promote timely, affordable access to modern and personalised lung cancer treatments across diverse healthcare settings Foster cross-sectoral collaboration and advocacy to drive investment and policy reform in lung cancer care Address stigma through education and empowerment to support early diagnosis, treatment adherence, and community acceptance A Region-Specific Approach to Lung Cancer Care The APAC Lung Cancer Policy Consensus is not just a regional adaptation of global recommendations; it is a comprehensive response to the distinct challenges faced by the APAC region. Unlike Western health systems that primarily focus on smoking-related lung cancer, the APAC region must contend with a higher prevalence of lung cancer in never-smokers due to factors such as environmental pollutants, and genetic predispositions. Moreover, the region's healthcare systems are highly heterogeneous, ranging from well-resourced settings with cutting-edge cancer care to lower-resource environments building on basic cancer services. Given these disparities, a one-size-fits-all approach would be ineffective. The APAC Lung Cancer Policy Consensus presents a regionally tailored action plan that offers specific strategies and targets to improve lung cancer care and outcomes, ensuring that every health system in the region, regardless of its capacity, can make progress toward the shared goals. 'We call on policymakers, healthcare leaders, and stakeholders across the APAC region to urgently prioritise and implement policies that improve lung cancer outcomes. While the specific solutions will vary across health systems, this consensus provides a shared foundation to guide national efforts. By acting now and adapting these recommendations to local contexts, we can foster a future where healthcare systems of all sizes work together to overcome regional challenges.' said Judy Li, Consortium Manager at ASPIRE for Lung Cancer. Looking Ahead The launch of the APAC Lung Cancer Policy Consensus marks the start of a sustained regional effort to transform lung cancer care in the Asia-Pacific region. Over the coming months, ASPIRE for Lung Cancer and its partners will continue to engage with policymakers, healthcare leaders, and patient advocacy groups to ensure that the consensus principles are translated into concrete action, with measurable outcomes. Through this regional collaboration, APAC aims to drive meaningful change that will improve survival rates and quality of life for lung cancer patients across the region. For more details about the APAC Lung Cancer Policy Consensus or to learn how you can get involved in advancing lung cancer care in your region, visit About ASPIRE for Lung Cancer ASPIRE (Asia Pacific Policy Review and Engagement) for Lung Cancer is a collaborative multilateral effort focused on improving lung cancer outcomes in the Asia-Pacific region through policy reforms. We advocate for prioritising lung cancer in government action plans, aiming to drive transformative changes that enhance patient access and care. We believe in the influence of collaboration and collective action to drive positive change. We therefore work with governments, agencies, NGOs and patient groups, bringing together multi-disciplinary experts to improve health outcomes for lung cancer patients in the APAC region. CONTACT: ASPIRE for Lung Cancer,
